Shockwave Buys Neovasc, Hoping Reducer Angina Device Complements Coronary Lithotripsy
Executive Summary
Shockwave, which markets lithotripsy technology to treat calcified vascular disease, will pay about $100m upfront and up to $47m more in potential milestones to buy Neovasc, the Vancouver, BC-based developer of the Reducer device to treat angina.